Fresenius debuts Actemra biosimilar
Fresenius, via its operating company Fresenius Kabi, is introducing Tyenne (tocilizumab-aazg), a biosimilar of Actemra (tocilizumab). Tyenne, for use in the treatment of chronic autoimmune diseases, is available in an intravenous formulation.
Michael Sen, CEO of Fresenius said, “With the launch of Tyenne in the U.S., we have reached another important milestone in accelerating our strong (Bio)Pharma momentum. Growing this platform is a substantial cornerstone of our #FutureFresenius journey. Overall, we have seen an excellent performance of our (Bio)Pharma business in 2024 so far. We are particularly happy with the good progress of our majority-owned biotechnology company mAbxience and the traction of Tyenne, the first tocilizumab biosimilar available in Europe since November 2023.”
Tyenne is the first tocilizumab biosimilar with an intravenous and subcutaneous formulation approved by the FDA. The biosimilar received FDA approval on March 5. Tyenne is Fresenius’ third approved biosimilar available in the U.S. and the second within its immunology portfolio. The biologic medicine is indicated for the treatment of several autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis.
[Read more: Fresenius Kabi intros generic Tepadina]
Pierluigi Antonelli, CEO of Fresenius Kabi said, “Tyenne will impact the treatment landscape for inflammatory and immune diseases in the U.S. Reaching ever more patients with our state-of-the-art biopharma portfolio signals a clear growth path in a highly promising market segment. We will continue to roll out our comprehensive pipeline of autoimmune and oncology biosimilars with several molecules in late-stage development.”
Supported by Fresenius Kabi’s support program for healthcare professionals and patients, the company’s biologic medicine provides wider access to more treatment options and contributes to the viability of healthcare systems.
Next to its two available biosimilars, Idacio (adalimumab) and Stimufend (pegfilgrastim), Fresenius Kabi has a growing pipeline of autoimmune and oncology biosimilars with several molecules in late-stage development.
[Read more: Fresenius Kabi intros generic Cytoxan]